Tim Illidge Selected Research

Immunoconjugates (Immunoconjugate)

12/2017	Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
3/2015	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tim Illidge Research Topics

Disease

16	Neoplasms (Cancer) 01/2023 - 01/2004
15	Lymphoma (Lymphomas) 11/2021 - 08/2006
14	Hodgkin Disease (Hodgkin's Disease) 11/2021 - 04/2013
5	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2021 - 02/2008
5	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 02/2008
5	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2018 - 06/2012
3	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 02/2007
3	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 02/2007
3	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2019 - 10/2014
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2018 - 12/2017
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 07/2011 - 07/2007
1	Oropharyngeal Neoplasms 10/2022
1	Hypoxia (Hypoxemia) 11/2021
1	Urinary Bladder Neoplasms (Bladder Cancer) 11/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2021
1	COVID-19 01/2020
1	Infections 01/2020
1	Diarrhea 01/2018
1	Anemia 01/2018
1	Leukopenia 01/2018
1	Kidney Neoplasms (Kidney Cancer) 11/2016
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2015
1	Disease Progression 04/2015
1	Hemorrhage 07/2007
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 08/2006
1	Brain Neoplasms (Brain Tumor) 01/2004

Drug/Important Bio-Agent (IBA)

9	Brentuximab VedotinIBA 01/2019 - 06/2012
8	Monoclonal AntibodiesIBA 01/2023 - 08/2005
6	Rituximab (Mabthera)FDA Link 01/2020 - 02/2008
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 10/2014
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 10/2014
4	Prednisone (Sone)FDA LinkGeneric 01/2019 - 10/2014
3	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 10/2014
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2019 - 04/2015
2	Dacarbazine (DIC)FDA LinkGeneric 01/2019 - 04/2015
2	Vinblastine (Vinblastine Sulfate)FDA Link 01/2019 - 04/2015
2	Immunoconjugates (Immunoconjugate)IBA 12/2017 - 03/2015
2	obinutuzumabIBA 11/2015 - 10/2014
2	ibritumomab tiuxetan (Zevalin)FDA Link 07/2007 - 08/2006
2	Yttrium-90IBA 07/2007 - 08/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2023
1	LigandsIBA 01/2023
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2023
1	B7-H1 AntigenIBA 11/2021
1	Oxygen (Dioxygen)IBA 11/2021
1	Procarbazine (Matulane)FDA Link 01/2019
1	Etoposide (VP 16)FDA LinkGeneric 01/2019
1	AntibodiesIBA 02/2007
1	AntigensIBA 02/2007
1	CD20 AntigensIBA 08/2006
1	Complement System Proteins (Complement)IBA 08/2005
1	motexafin gadoliniumIBA 01/2004

Therapy/Procedure

20	Radiotherapy 01/2023 - 01/2004
13	Therapeutics 01/2023 - 08/2006
8	Drug Therapy (Chemotherapy) 10/2022 - 08/2008
6	Radioimmunotherapy 01/2020 - 08/2006
2	Stem Cell Transplantation 01/2018 - 07/2007
2	Immunotherapy 11/2016 - 02/2008
1	Image-Guided Radiotherapy 07/2014
1	Homologous Transplantation 04/2013
1	Combined Modality Therapy 07/2011
1	Induction Chemotherapy 02/2008